adenosine has been researched along with Animal Mammary Carcinoma in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 1 (50.00) | 2.80 |
Authors | Studies |
---|---|
Badou, A; Benthami, H; Chraa, D; Elkarroumi, M; Karkouri, M; Olive, D; Razzouki, I; Rezouki, I; Zohair, B | 1 |
Borst, P; Greenberger, L; Jonkers, J; Rottenberg, S; Sol, W; van Tellingen, O; Zander, SA; Zhang, Y | 1 |
2 other study(ies) available for adenosine and Animal Mammary Carcinoma
Article | Year |
---|---|
The immune checkpoint adenosine 2A receptor is associated with aggressive clinical outcomes and reflects an immunosuppressive tumor microenvironment in human breast cancer.
Topics: Adenosine; Algorithms; Animals; Breast Neoplasms; Female; Humans; Mammary Neoplasms, Animal; Tumor Microenvironment | 2023 |
EZN-2208 (PEG-SN38) overcomes ABCG2-mediated topotecan resistance in BRCA1-deficient mouse mammary tumors.
Topics: Adenosine; Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; BRCA1 Protein; Camptothecin; Diketopiperazines; DNA Topoisomerases, Type I; Female; Gene Expression; Heterocyclic Compounds, 4 or More Rings; Irinotecan; Mammary Glands, Animal; Mammary Neoplasms, Animal; Mice; Mice, Knockout; Mutation; Polyethylene Glycols; Survival Rate; Topoisomerase I Inhibitors; Topotecan | 2012 |